Sign in or create an account to add this stock to your watchlist.
About Foundation Medicine (NASDAQ:FMI)
Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.
Industry, Sector and Symbol
Industry Medical laboratories
Trailing P/E Ratio-22.66
Forward P/E Ratio-23.60
Sales & Book Value
Annual Sales$152.90 million
Price / Sales24.70
Price / CashN/A
Book Value$0.87 per share
Price / Book117.18
EPS (Most Recent Fiscal Year)($4.50)
Return on Equity-299.63%
Return on Assets-94.81%
Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions
What is Foundation Medicine's stock symbol?
Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."
How were Foundation Medicine's earnings last quarter?
Foundation Medicine Inc (NASDAQ:FMI) released its quarterly earnings data on Wednesday, May, 2nd. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.08. The business earned $52.84 million during the quarter, compared to analyst estimates of $44.99 million. Foundation Medicine had a negative net margin of 84.96% and a negative return on equity of 299.63%. Foundation Medicine's quarterly revenue was up 100.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.31) EPS. View Foundation Medicine's Earnings History.
When is Foundation Medicine's next earnings date?
What price target have analysts set for FMI?
3 Wall Street analysts have issued twelve-month price objectives for Foundation Medicine's shares. Their predictions range from $73.00 to $90.00. On average, they expect Foundation Medicine's stock price to reach $81.00 in the next twelve months. View Analyst Ratings for Foundation Medicine.
Who are some of Foundation Medicine's key competitors?
Some companies that are related to Foundation Medicine include ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), InVitae (NVTA), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Celcuity (CELC), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS) and Cancer Genetics (CGIX).
Who are Foundation Medicine's key executives?
Foundation Medicine's management team includes the folowing people:
- Mr. Alexis Borisy, Co-Founder, Founding Advisor & Independent Director (Age 46)
- Mr. Troy Cox, CEO, Pres & Director (Age 54)
- Mr. Jason Ryan, CFO & Principal Accounting Officer (Age 44)
- Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)
- Mr. Tom Godden, Chief Information Officer
Has Foundation Medicine been receiving favorable news coverage?
News coverage about FMI stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foundation Medicine earned a news impact score of 0.13 on Accern's scale. They also gave media coverage about the company an impact score of 45.80 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Foundation Medicine's major shareholders?
Foundation Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.71%), Lord Abbett & CO. LLC (1.66%), Baillie Gifford & Co. (1.05%), Amundi Pioneer Asset Management Inc. (0.74%), Elk Creek Partners LLC (0.37%) and Highbridge Capital Management LLC (0.29%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.
Which institutional investors are selling Foundation Medicine stock?
FMI stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Pier Capital LLC, Platinum Investment Management Ltd., Employees Retirement System of Texas, A.R.T. Advisors LLC, California Public Employees Retirement System and DekaBank Deutsche Girozentrale. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.
Which institutional investors are buying Foundation Medicine stock?
FMI stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Highbridge Capital Management LLC, PointState Capital LP, Franklin Resources Inc., Baillie Gifford & Co., UBS Group AG, Trexquant Investment LP and Lord Abbett & CO. LLC. View Insider Buying and Selling for Foundation Medicine.
How do I buy shares of Foundation Medicine?
Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Foundation Medicine's stock price today?
One share of FMI stock can currently be purchased for approximately $101.95.
How big of a company is Foundation Medicine?
Foundation Medicine has a market capitalization of $3.78 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe.
How can I contact Foundation Medicine?
Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected]
MarketBeat Community Rating for Foundation Medicine (FMI)MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Foundation Medicine (NASDAQ:FMI) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Foundation Medicine in the last 12 months. Their average twelve-month price target is $81.00, suggesting that the stock has a possible downside of 20.55%. The high price target for FMI is $90.00 and the low price target for FMI is $73.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Buy||Buy|
|Consensus Rating Score: ||2.33||2.33||2.60||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$81.00||$81.00||$70.50||$35.00|
|Price Target Upside: ||20.55% downside||2.70% downside||15.32% downside||5.42% upside|
Foundation Medicine (NASDAQ:FMI) Consensus Price Target History
Foundation Medicine (NASDAQ:FMI) Analyst Ratings History
(Data available from 6/17/2016 forward)
Foundation Medicine (NASDAQ:FMI) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Foundation Medicine (NASDAQ FMI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 33.47%
Foundation Medicine (NASDAQ FMI) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/21/2018||Vincent A Miller||Insider||Sell||1,570||$85.00||$133,450.00|| |
|5/16/2018||Troy Cox||CEO||Sell||2,157||$77.10||$166,304.70|| |
|5/7/2018||Troy Cox||CEO||Sell||7,063||$70.01||$494,480.63||245,627|| |
|4/16/2018||Jason Ryan||CFO||Sell||3,449||$74.30||$256,260.70||52,573|| |
|4/16/2018||Michael J Pellini||Director||Sell||3,500||$74.65||$261,275.00||110,711|| |
|4/16/2018||Vincent A Miller||Insider||Sell||3,283||$74.02||$243,007.66||70,088|| |
|4/3/2018||Michael J Pellini||Director||Sell||13,659||$70.28||$959,954.52||114,211|| |
|4/2/2018||Jason Ryan||CFO||Sell||6,139||$76.23||$467,975.97|| |
|4/2/2018||Konstantin Fiedler||COO||Sell||358||$74.88||$26,807.04|| |
|4/2/2018||Michael J. Doherty||Insider||Sell||8,190||$74.87||$613,185.30|| |
|4/2/2018||Robert W Hesslein||SVP||Sell||1,585||$74.88||$118,684.80|| |
|3/15/2018||Jason Ryan||CFO||Sell||15,000||$78.26||$1,173,900.00|| |
|3/15/2018||Michael J Pellini||Director||Sell||3,500||$78.29||$274,015.00|| |
|2/20/2018||Vincent A Miller||Insider||Sell||32,008||$76.87||$2,460,454.96|| |
|2/15/2018||Jason Ryan||CFO||Sell||15,000||$67.53||$1,012,950.00|| |
|2/15/2018||Michael J Pellini||Director||Sell||17,324||$67.69||$1,172,661.56|| |
|2/15/2018||Troy Cox||CEO||Sell||9,012||$67.22||$605,786.64|| |
|2/13/2018||Steven J Kafka||COO||Sell||29,791||$61.55||$1,833,636.05|| |
|2/7/2018||Steven J Kafka||COO||Sell||23,064||$70.13||$1,617,478.32||61,361|| |
|2/7/2018||Troy Cox||CEO||Sell||26,713||$70.13||$1,873,382.69||224,345|| |
|1/29/2018||Vincent A Miller||Insider||Sell||4,400||$75.00||$330,000.00||97,722|| |
|1/22/2018||Vincent A Miller||Insider||Sell||17,187||$70.27||$1,207,730.49||110,509|| |
|1/17/2018||Michael J Pellini||Director||Sell||37,288||$64.55||$2,406,940.40|| |
|1/17/2018||Vincent A Miller||Insider||Sell||14,755||$65.31||$963,649.05|| |
|1/16/2018||Jason Ryan||CFO||Sell||21,035||$64.38||$1,354,233.30|| |
|1/16/2018||Robert W Hesslein||SVP||Sell||18,021||$64.30||$1,158,750.30|| |
|1/16/2018||Steven J Kafka||COO||Sell||4,148||$65.71||$272,565.08|| |
|1/2/2018||Jason Ryan||CFO||Sell||2,336||$64.00||$149,504.00|| |
|1/2/2018||Robert W. Hesslein||SVP||Sell||1,864||$64.00||$119,296.00|| |
|1/2/2018||Steven J. Kafka||COO||Sell||157||$64.00||$10,048.00|| |
|1/2/2018||Vincent A Miller||Insider||Sell||2,349||$64.00||$150,336.00||99,484|| |
|12/13/2017||Evan/ Fa Jones||Director||Sell||1,400||$62.05||$86,870.00||17,652|| |
|12/6/2017||Evan/ Fa Jones||Director||Sell||6,500||$60.66||$394,290.00||19,652|| |
|12/6/2017||Steven J Kafka||COO||Sell||5,774||$58.57||$338,183.18||96,761|| |
|12/5/2017||Jason Ryan||CFO||Sell||21,726||$61.26||$1,330,934.76||55,639|| |
|12/5/2017||Vincent A Miller||Insider||Sell||20,000||$61.17||$1,223,400.00||99,984|| |
|11/2/2017||Jason Ryan||CFO||Sell||9,731||$50.00||$486,550.00||52,601|| |
|10/13/2017||Steven J Kafka||COO||Sell||3,361||$44.62||$149,967.82|| |
|10/12/2017||Jason Ryan||CFO||Sell||1,152||$45.05||$51,897.60|| |
|10/2/2017||Jason Ryan||CFO||Sell||3,154||$38.80||$122,375.20|| |
|10/2/2017||Michael J Pellini||Director||Sell||4,349||$38.80||$168,741.20|| |
|10/2/2017||Robert W Hesslein||SVP||Sell||2,165||$38.80||$84,002.00|| |
|10/2/2017||Steven J Kafka||COO||Sell||3,201||$38.80||$124,198.80|| |
|10/2/2017||Vincent A Miller||Insider||Sell||2,944||$38.80||$114,227.20|| |
|8/9/2017||David Daly||Insider||Sell||46,872||$39.50||$1,851,444.00||163,133|| |
|8/9/2017||Michael J Pellini||Director||Sell||30,000||$39.52||$1,185,600.00||275,077|| |
|8/8/2017||Krishna Yeshwant||Director||Sell||4,800||$40.01||$192,048.00||5,786|| |
|8/4/2017||Krishna Yeshwant||Director||Sell||18,072||$36.85||$665,953.20||5,786|| |
|7/14/2017||Steven J Kafka||COO||Sell||11,781||$39.15||$461,226.15||97,549|| |
|7/13/2017||Jason Ryan||CFO||Sell||5,084||$39.77||$202,190.68||66,638|| |
|7/6/2017||David Daly||Insider||Sell||6,316||$38.84||$245,313.44|| |
|7/6/2017||Jason Ryan||CFO||Sell||6,683||$38.84||$259,567.72|| |
|7/6/2017||Michael J. Pellini||Director||Sell||15,856||$38.84||$615,847.04|| |
|7/6/2017||Robert W. Hesslein||SVP||Sell||5,070||$38.84||$196,918.80|| |
|7/6/2017||Steven J Kafka||COO||Sell||19,708||$38.93||$767,232.44||116,728|| |
|7/5/2017||Steven J Kafka||COO||Sell||12,310||$38.98||$479,843.80||116,728|| |
|6/2/2017||Jason Ryan||CFO||Sell||5,573||$40.00||$222,920.00||78,405|| |
|6/1/2017||David Daly||Insider||Sell||555||$38.30||$21,256.50|| |
|4/18/2017||Jason Ryan||CFO||Sell||503||$34.55||$17,378.65||51,244|| |
|4/18/2017||Steven J Kafka||COO||Sell||4,405||$34.55||$152,192.75||129,038|| |
|4/3/2017||David Daly||Insider||Sell||2,070||$31.96||$66,157.20|| |
|4/3/2017||Michael J. Pellini||Director||Sell||1,700||$31.96||$54,332.00|| |
|4/3/2017||Robert W. Hesslein||SVP||Sell||1,233||$31.96||$39,406.68|| |
|4/3/2017||Steven J. Kafka||COO||Sell||2,157||$31.96||$68,937.72|| |
|3/16/2017||Jason Ryan||CFO||Sell||12,500||$31.68||$396,000.00||56,230|| |
|3/16/2017||Robert W Hesslein||SVP||Sell||6,231||$31.67||$197,335.77||104,305|| |
|3/8/2017||Michael J Pellini||Director||Sell||40,000||$34.30||$1,372,000.00||353,144|| |
|2/8/2017||Steven J Kafka||COO||Sell||10,415||$23.24||$242,044.60||146,015|| |
|1/13/2017||Jason Ryan||CFO||Sell||1,777||$19.00||$33,763.00||52,980|| |
|1/4/2017||David Daly||Insider||Sell||5,097||$17.91||$91,287.27|| |
|1/4/2017||Jason Ryan||CFO||Sell||4,665||$17.74||$82,757.10|| |
|1/4/2017||Michael J. Pellini||CEO||Sell||14,637||$17.67||$258,635.79|| |
|1/4/2017||Robert W. Hesslein||SVP||Sell||4,682||$17.74||$83,058.68|| |
|1/4/2017||Steven J. Kafka||COO||Sell||8,390||$17.72||$148,670.80|| |
|12/1/2016||David Daly||Insider||Sell||564||$19.95||$11,251.80|| |
|11/22/2016||Steven J Kafka||COO||Sell||6,273||$23.01||$144,341.73||103,009|| |
|10/20/2016||Jason Ryan||CFO||Sell||506||$22.45||$11,359.70||59,422|| |
|10/20/2016||Steven J Kafka||COO||Sell||4,427||$23.00||$101,821.00||101,550|| |
|10/4/2016||David Daly||Insider||Sell||2,045||$23.65||$48,364.25|| |
|10/4/2016||Michael J. Pellini||CEO||Sell||2,629||$23.65||$62,175.85|| |
|10/4/2016||Robert W. Hesslein||SVP||Sell||1,220||$23.65||$28,853.00|| |
|10/4/2016||Steven J. Kafka||COO||Sell||2,135||$23.62||$50,428.70|| |
|9/20/2016||Steven J Kafka||COO||Sell||9,469||$23.70||$224,415.30||108,112|| |
|8/19/2016||Jason Ryan||CFO||Sell||13,863||$23.92||$331,602.96||61,148|| |
|7/5/2016||David Daly||Insider||Sell||5,008||$17.76||$88,942.08|| |
|7/5/2016||Jason Ryan||CFO||Sell||4,687||$17.63||$82,631.81|| |
|7/5/2016||Michael J. Pellini||CEO||Sell||10,160||$17.63||$179,120.80|| |
|7/5/2016||Robert W. Hesslein||SVP||Sell||4,705||$17.62||$82,902.10|| |
|7/5/2016||Steven J. Kafka||COO||Sell||6,495||$17.67||$114,766.65|| |
|6/3/2016||David Daly||Insider||Sell||472||$21.66||$10,223.52||114,458|| |
|4/1/2016||Steven J Kafka||COO||Sell||124||$18.08||$2,241.92||41,226|| |
|4/1/2016||Vincent A Miller||Insider||Sell||356||$18.08||$6,436.48||78,482|| |
|12/1/2015||David Daly||Insider||Sell||2,559||$16.78||$42,940.02||45,631|| |
|11/13/2015||Michael J Pellini||CEO||Buy||9,100||$16.43||$149,513.00||174,025|| |
|6/15/2015||Krishna Yeshwant||Director||Sell||183,860||$32.98||$6,063,702.80|| |
|4/7/2015||Alexis Borisy||Director||Sell||234,542||$50.00||$11,727,100.00|| |
|4/7/2015||Roche Holdings Inc||Insider||Buy||15,604,288||$50.00||$780,214,400.00|| |
|4/7/2015||Rock Ventures Lp Third||Major Shareholder||Sell||3,976,278||$50.00||$198,813,900.00|| |
|3/5/2015||Michael J Pellini||CEO||Sell||153,300||$47.24||$7,241,892.00|| |
|1/15/2015||Steven J Kafka||COO||Sell||15,000||$48.38||$725,700.00|| |
|1/12/2015||Michael J Pellini||CEO||Sell||22,500||$51.07||$1,149,075.00|| |
|1/12/2015||Robert W Hesslein||SVP||Sell||7,000||$52.11||$364,770.00|| |
|1/12/2015||Steven J Kafka||COO||Sell||8,000||$51.83||$414,640.00|| |
|1/12/2015||Vincent A Miller||Insider||Sell||2,000||$53.03||$106,060.00|| |
|1/8/2015||Robert W Hesslein||SVP||Sell||4,000||$23.03||$92,120.00|| |
|12/29/2014||Michael J Pellini||CEO||Sell||12,500||$23.91||$298,875.00|| |
|11/17/2014||Jason Ryan||SVP||Sell||3,541||$24.90||$88,170.90|| |
|11/14/2014||Michael J Pellini||CEO||Sell||12,500||$24.91||$311,375.00|| |
|10/27/2014||Jason Ryan||SVP||Sell||2,360||$25.00||$59,000.00|| |
|10/27/2014||Steven J Kafka||COO||Sell||10,000||$25.31||$253,100.00|| |
|9/15/2014||Jason Ryan||SVP||Sell||2,361||$21.92||$51,753.12|| |
|8/18/2014||Michael J Pellini||CEO||Sell||12,500||$25.29||$316,125.00|| |
|7/22/2014||Steven J Kafka||COO||Sell||10,000||$27.14||$271,400.00|| |
|7/15/2014||Jason Ryan||SVP||Sell||3,541||$27.22||$96,386.02|| |
|7/15/2014||Vincent A Miller||Insider||Sell||15,000||$27.25||$408,750.00|| |
|7/8/2014||Robert W Hesslein||SVP||Sell||4,000||$27.22||$108,880.00|| |
|7/2/2014||Michael J Pellini||CEO||Sell||15,000||$27.42||$411,300.00|| |
|6/26/2014||Jason Ryan||SVP||Sell||1,180||$25.00||$29,500.00|| |
|6/26/2014||Steven J Kafka||COO||Sell||5,000||$25.19||$125,950.00|| |
|6/19/2014||Steven J Kafka||COO||Sell||5,000||$24.46||$122,300.00|| |
|6/16/2014||Jason Ryan||SVP||Sell||2,361||$22.61||$53,382.21|| |
|6/13/2014||Krishna Yeshwant||Director||Sell||1,300,000||$22.40||$29,120,000.00|| |
|6/5/2014||Jason Ryan||SVP||Sell||10,000||$24.06||$240,600.00|| |
|6/5/2014||Steven J Kafka||COO||Sell||4,500||$24.19||$108,855.00|| |
|5/6/2014||Vincent Miller||Insider||Sell||3,000||$30.00||$90,000.00||117,000|| |
|4/16/2014||Jason Ryan||SVP||Sell||3,541||$26.36||$93,340.76|| |
|4/16/2014||Vincent Miller||Insider||Sell||30,000||$26.86||$805,800.00||120,000|| |
Foundation Medicine (NASDAQ FMI) News Headlines
Foundation Medicine (NASDAQ:FMI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Foundation Medicine (NASDAQ:FMI) Income Statement, Balance Sheet and Cash Flow Statement
Foundation Medicine (NASDAQ FMI) Stock Chart for Sunday, June, 17, 2018